US Patent Issued to SparX Bioscience on Nov. 4 for "Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases" (Illinois, Maryland Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,460,005, issued on Nov. 4, was assigned to SparX Bioscience Ltd. (Tortola, British Virgin Islands).

"Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases" was invented by Guidong Zhu (Gurnee, Ill.), Jingdong Ye (Vernon Hills, Ill.), Jingdong Qin (Woodridge, Ill.) and Jichun Ma (Germantown, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related...